August 9, 2021 – Thermo Fisher Scientific, the world leader in serving science, today announced it has updated its Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel to detect the Delta and Lambda strains.
The research panel features a customizable menu of verified real-time PCR assays for identification of SARS-CoV-2 mutations. The panel enables laboratories to track known mutations by selecting from a menu of over 50 assays designed to screen for different variants. The TaqMan SARS-CoV-2 Mutation Panel allows up to hundreds of samples to be run to identify one or multiple mutations so labs can scale their surveillance operations based on testing need.
The TaqMan SARS-CoV-2 Mutation Panel provides results in about an hour and is based on TaqMan SNP genotyping assay technology, which helps detect and distinguish mutations efficiently, the company says.
The panel can be used with real-time PCR instruments and technology widely used in labs globally.
For research use only. Not for use in diagnostic procedures.